Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

Blood

Volumn 110, Issue 4, 2007, Pages 1178-1183

  Galli, Monica ^a   Borrelli, Giovanna ^b   Jacobsen, Eva Marie ^c   Marfisi, Rosa Maria ^b   Finazzi, Guido ^a   Marchioli, Roberto ^b   Wisloff, Finn ^c   Marziali, Stefana ^a   Morboeuf, Olivier ^d   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Diagnostica Stago   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PROTHROMBIN; WARFARIN;

ABORTION; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VEIN THROMBOSIS;

EID: 34548038654     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-066043     Document Type: Article

References (34)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
3. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 990;334:1544-1547.
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990;336:177-178.
5. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66:629-632.
6. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
7. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486-491.
8. de Laat B, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540-1545.
9. Simmelink MJA, Horbach DA, Derksen RHWM, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipids surfaces. Br J Haematol. 2001;113:621-629.
10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832.
11. Galli M, Luciani D, Bertolini G, Barbui T. Antiβ2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003;102:2717-2723.
12. de Laat BH, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. β2GPI-dependent lupus anticoagulant activity highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104:3598-3602.
13. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005;93:1147-1152.
14. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanisms? Blood. 1993;81:2618-2625.
15. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol. 1994;47:56-58.
16. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid sindrome (WAPS). J Thromb Haemost. 2005;3:848-853.
17. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
18. th, 1986. Clin Exp Immunol. 1987;68:215-222.
19. Schjetlein R, Sletness KE, Wisloff F. A quantitative, semi-automated and computer-assisted test for lupus anticoagulant. Thromb Res. 1993;69:239-250.
20. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisloff F. The Lupus Ratio test - An inter-laboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants - ISLA 5. Thromb Haemost. 2000;83:704-708.
21. Liestoll S, Jacobsen EM, Wisloff F. Dilute prothrombin time-based lupus ratio test: integrated LA testing with recombinant tissue thromboplastin. Thromb Res. 2002;105:177-182.
22. Galli M, Willems GM, Rosing J, et al. Anti-prothrombin IgG from patients aith anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol. 2005;129:240-247.
23. Field SL, Hogg PJ, Daly EB, et al. Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood. 1999;94:3421-3431.
24. Forasteiro R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231-1238.
25. Van Heerde WL, Lap P, Schoormans S, de Groot PG, Reutelingsperger CPM, Vroom TM. Localization of annexin A5 in human tissues. Annexins. 2004;1:56-62.
26. De Laat B, Derksen RH, Mackie IJ, et al. Annexin A5 polymorphism (-1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis. 2006;65:1468-1472.
27. van Ommen CH, van Wijnen M, de Groot PG, van der Horst CM, Peters M. Postvaricella purpura fulminans caused by acquired protein S deficiency resulting from antiprotein S antibodies: search for the epitopes. J Pediatr Hematol Oncol. 2002;24:413-416.
28. Kurugol Z, Vardar F, Ozkinay F, Kavakli K, Ozkinay C. Lupus anticoagulant and protein S defi-ciency in otherwise healthy children with acute varicella infection. Acta Pediatr. 2000;89:1186-1189.
29. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol. 1994;87:94-99.
30. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European concerted action on thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human β2-glycoprotein I. Thromb Haemost. 1999;81:929-934.
31. Jennings I, Mackie I, Arnout J, Preston FE. Lupus anticoagulant testing with plasmas spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost. 2004;2:2178-2184.
32. Schulman S, Svenungsson E, Granqvist S, and the Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332-338.
33. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thrombembolism. N Engl J Med. 1999;340:901-907.
34. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.